Savillex LLC has completed its acquisition of Entegris Inc.'s Life Sciences Fluid Management business. Savillex, based in Eden Prairie, Minn., supplies high-purity fluid handling solutions for life science and laboratory applications worldwide. Entegris is based in Billerica, Mass.
The acquired portfolio includes bioprocessing and pharmaceutical manufacturing solutions, including Aramus and PE bags, single-use assemblies, and components used across discovery, clinical and commercial manufacturing. Savillex said the acquisition expands its life sciences offerings with an enhanced portfolio of high-performance single-use solutions.
Expanded single-use portfolio
Savillex is taking on the Life Sciences Fluid Management team and its technologies in high-purity fluid management. According to the company, customers can expect expanded single-use solutions, increased technical expertise and enhanced capabilities for applications ranging from early-stage research through commercial manufacturing. Savillex said the combination of complementary strengths is intended to deliver greater value and help customers simplify increasingly complex bioprocessing workflows.
Eric Giesing, chief executive officer of Savillex, said the acquired business has built a strong reputation in high-purity single-use bioprocessing. He said the Aramus product line is a natural fit alongside Savillex's containment and bioprocessing offerings. Giesing added that the acquisition expands the company's portfolio and enables it to offer a broader range of innovative solutions to biopharmaceutical and pharmaceutical customers. He also said Savillex is investing in technologies that help customers accelerate the development and production of critical therapies.
Chris Bedi, general manager of Fluid Management at Savillex, said the transaction creates an opportunity to offer a broader portfolio of high-value fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide. He said the Fluid Management portfolio complements Savillex's existing capabilities. The combined organization, he added, will continue to provide innovative solutions while expanding its ability to support partners across the continuum of drug development.
Savillex said the acquisition adds a portfolio that covers bags, assemblies and components across multiple production stages. The company said these products are used in discovery, clinical and commercial manufacturing, and it expects the deal to deepen its technical expertise in high-purity fluid management.
Strategy and transaction advisers
Savillex said the transaction advances its strategy of delivering industry-leading solutions for the life sciences market. The company said it remains committed to investing in innovation, quality and customer partnerships while expanding its portfolio to meet the evolving needs of biopharmaceutical and pharmaceutical manufacturers worldwide.
EC M&A served as financial advisor to Savillex, and Sidley Austin LLP served as legal counsel. The terms of the transaction were not disclosed.